Azitrix

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azitrix

Property Description
Active ingredient Azithromycin
Form Tablets, capsules, oral suspension, IV solution
Pharmacological class Macrolide Antibiotic (Azalide)
General purpose Addressing bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is Azitrix and What is its Purpose?

Azitrix is a medicinal product containing the active ingredient Azithromycin, which functions as a prescription-only, broad-spectrum antibacterial agent. It is classified as a macrolide antibiotic, and belongs to the unique subcategory known as the azalides. The general purpose of this medication is to address various bacterial infections by targeting and halting the growth of susceptible bacterial pathogens in scenarios such as acute respiratory illness or skin infections.

Azithromycin is a semi-synthetic derivative that was chemically modified from the older macrolide antibiotic, Erythromycin. Azithromycin is a second-generation macrolide, clinically recognized for its enhanced pharmacokinetic properties compared to its predecessors. This means the drug has structural features designed to improve its effectiveness and duration of action in the body.

Azithromycin: Composition, Origin, and Unique Classification

The core composition of Azitrix is the single active compound Azithromycin, combined with excipients required for stability and delivery. The drug’s mechanism principle involves acting as a bacteriostatic agent, which means its primary role is to control the bacterial population by preventing its proliferation. Azithromycin achieves this via the inhibition of protein synthesis in susceptible bacteria.

Azitrix is supplied in multiple high-level dosage form(s) to suit different clinical requirements, including tablets, capsules, oral suspension, and formulations for intravenous solution. These forms allow the medication to be administered by both the Oral and Intravenous route of administration, ensuring flexible delivery to target bacterial pathogens.

Regulatory References

  1. Azithromycin - StatPearls - NCBI Bookshelf
  2. NIH MedlinePlus Drug Information

What side effects are possible with Azitrix?

Possible Side Effects and Safety Information for Azitrix

Azitrix is generally associated with gastrointestinal adverse reactions, but carries warnings for serious and clinically significant effects on the heart, liver, and immune system.

Adverse Reaction Scope

Classification Common Reactions Serious/Clinically Significant Reactions
System-Organ Classes Gastrointestinal, Nervous System, Skin Cardiac, Hepatobiliary, Hypersensitivity
Common (ge 1/100 to < 1/10) Diarrhea, Nausea, Abdominal pain, Vomiting, Headache, Dizziness Prolonged QT interval, Torsades de pointes (a potentially fatal heart rhythm)
Uncommon to Rare Rash, Pruritus, Photosensitivity, Palpitations, Hepatitis, Vertigo Fatal allergic reactions (e.g., Anaphylaxis, Angioedema) and severe skin reactions (e.g., SJS, TEN, DRESS), Fatal Hepatotoxicity (hepatic necrosis/failure), Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates, Clostridioides difficile-Associated Diarrhea (CDAD)

Population-Specific Safety Considerations

  • Neonates (up to 42 days of life): The risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) has been reported, requiring monitoring for vomiting or irritability with feeding.
  • Cardiovascular Risk Patients: Caution is advised in patients with existing QT interval prolongation, uncorrected electrolyte imbalances (hypokalemia/hypomagnesemia), or those receiving other QT-prolonging drugs. Observational studies have noted an increased short-term potential risk of acute cardiovascular death in the first 5 days of use compared to other antibacterial drugs.
  • Myasthenia Gravis: Azitrix may exacerbate muscle weakness in individuals with this condition.
  • Severe Renal Impairment (GFR < 10 mL/min): Systemic exposure to the drug is increased, necessitating caution.

Restrictions and Monitoring Notes

Azitrix is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with previous use of the drug. Treatment must be immediately discontinued if signs of hepatitis, jaundice, or a severe allergic/skin reaction develop. The theoretical possibility of ergotism restricts its concomitant use with ergot derivatives. Patients must be monitored for signs of Clostridioides difficile associated diarrhea and superinfection with non-susceptible organisms.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived from official governmental regulatory documents regarding overdose situations for the active ingredient Azithromycin.

Overdose is generally defined as the ingestion of doses substantially exceeding the normal therapeutic range. The primary clinical manifestations documented following an acute overdose include severe, exaggerated gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, and a documented risk of reversible hearing loss.


Serious Outcomes and Required Actions

The most serious outcomes documented in regulatory prescribing information involve cardiac arrhythmias. Severe overdose carries a risk of QT interval prolongation and the potentially life-threatening arrhythmia Torsades de Pointes (TdP).

Due to this risk, the regulatory instruction is to seek immediate medical attention upon suspected overdose. Management is officially described as symptomatic and supportive treatment.

Supportive Care and Monitoring

Official labeling states that no specific antidote is known for Azithromycin overdose. Management requires hospital monitoring, including continuous Electrocardiogram (ECG) monitoring, to evaluate cardiac status. Furthermore, due to the drug’s extensive tissue distribution, regulatory guidance notes that procedural measures like dialysis are not beneficial in removing Azithromycin from the body.

Therapeutic Uses of Azitrix

What Azitrix treats: main uses and benefits

Azitrix is prescribed to address various bacterial infections in both adult and pediatric patients. Its primary therapeutic domains involve certain infections of the respiratory tract, skin, and reproductive organs.

Quick Facts

  • Respiratory Support: Used to manage community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
  • Infections of the Ear and Sinus: Utilized in the management of acute bacterial sinusitis and acute otitis media (ear infection) in children.
  • Skin and Tissue: Addresses uncomplicated infections involving the skin and underlying tissues.
  • Reproductive Health: Employed to treat certain sexually transmitted infections, including urethritis, cervicitis, and genital ulcer disease caused by specific susceptible bacteria.

Azitrix is part of a therapeutic regimen that aims to control the spread of susceptible bacteria, thereby contributing to the resolution of the infection. Use of this medication is reserved for infections that are proven or strongly suspected to be caused by bacteria, as determined by a healthcare provider. It is not effective against viral infections such as the common cold or flu.

Eligibility and Restrictions for Use

Eligibility for Azitrix

Azitrix (azithromycin) must not be used by individuals with a known hypersensitivity or allergy to azithromycin, erythromycin, or any macrolide or ketolide antibiotic. Use is also contraindicated if you have a history of cholestatic jaundice or liver dysfunction related to prior use of this medicine.

Populations Requiring Special Consideration

Patient Group Eligibility Status/Condition
Cardiovascular Risk Caution is required in patients with pre-existing QT prolongation, a history of Torsades de Pointes, or conditions like clinically relevant bradycardia or unstable electrolyte levels (low potassium/magnesium), due to an increased risk of heart rhythm issues.
Hepatic Function Use is not recommended in cases of severe hepatic impairment. Caution is advised for patients with significant liver disease.
Renal Function Caution is advised for patients with severe renal impairment (GFR < 10 mL/min).
Myasthenia Gravis Use requires caution as it may exacerbate muscle weakness.
Pediatric Patients Safety and effectiveness are not established in infants under 6 months of age. Tablet forms are typically not recommended for children weighing less than 45 kg.
Pregnancy/Lactation Should only be used during pregnancy if the benefit outweighs the potential risk. Breastfeeding should be discontinued during treatment, as the drug passes into breast milk.

Azitrix should also not be taken with certain medications, such as ergot derivatives, due to the theoretical risk of ergotism. It is not suitable for treating severe infections requiring a rapid, high blood concentration of the antibiotic.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Azitrix (Azithromycin) is based on official regulatory findings concerning specific pharmacokinetic and pharmacodynamic constraints. Regulatory bodies classify several co-administered substances as having clinically significant interactions.


Official Interaction Statements

  • Cardiac Conduction Risk: Co-administration with medicinal products known to prolong the QT interval (e.g., certain Class IA and Class III antiarrhythmics, Pimozide) is restricted or requires caution due to a pharmacodynamic risk of additive effects on cardiac repolarization.
  • Absorption Interference: Oral Azithromycin absorption may be decreased by co-administration with antacids containing aluminum or magnesium. Regulatory documents mandate that oral Azithromycin must be administered at least 2 hours before or 2 hours after these antacids.
  • Oral Anticoagulants: Post-marketing reports document that Azitrix may potentiate the effects of oral anticoagulants, such as Warfarin, requiring close monitoring of the International Normalized Ratio (INR).
  • P-glycoprotein (P-gp) Substrates: Azithromycin can potentially increase the systemic exposure of co-administered medicines that are sensitive P-gp substrates, including Digoxin.
  • Nelfinavir: Co-administration with the HIV protease inhibitor Nelfinavir is officially documented to increase the plasma concentration (AUC and Cmax) of Azitrix.
  • CYP450 Enzymes: Interaction studies consistently report that Azithromycin does not significantly interact with the hepatic cytochrome P450 enzyme system, such as CYP3A4, distinguishing it from some other macrolides.

Population-Specific Notes

Official labeling indicates that Azithromycin exposure is significantly increased in patients with severe renal impairment. Furthermore, Azitrix should not be given to patients with severe liver disease due to the lack of adequate pharmacokinetic data in this population.

Mechanism of Action

How Azitrix Works: Mechanism of Action

Azitrix's core action is achieved through steric inhibition by binding to the 23S ribosomal RNA (rRNA) component of the bacterial 50S ribosomal subunit . This molecular blockade obstructs the ribosome's exit tunnel, preventing peptide chain elongation and arresting the pathogen's ability to produce essential proteins and enzymes. This results in a bacteriostatic effect that halts the proliferation of the bacterial population.

The mechanism is complemented by the drug's unique ability to be taken up and concentrated within the host's phagocytic immune cells (macrophages and neutrophils). These cells deliver the compound directly to the infected tissue, resulting in a sustained local suppression of bacterial growth known as the Post-Antibiotic Effect (PAE), where the suppression persists after the drug concentration in the bloodstream has declined.

Efficacy is constrained by bacterial counter-mechanisms, primarily ribosomal target methylation (via erm genes) and active efflux pumps (e.g., mef genes). If the target is modified or the drug is pumped out, the fundamental inhibitory cascade is interrupted, preventing the halting of bacterial proliferation.

Dosage and Administration Information

How to Use Azitrix

Azitrix (Azithromycin) is administered based on prescribing information, which details the approved routes, frequency, and duration of use. The medication is primarily used through a short-duration, once-daily regimen.


Official Administration Protocols

Feature Official Labeled Instruction
Route of Administration Oral (Tablets, capsules, suspension) or Intravenous (IV) Infusion in a clinical setting.
Standard Dosing Common adult courses are 1500 mg total over 3 days (500 mg daily) or 5 days (500 mg Day 1, then 250 mg daily). A 1000 mg single oral dose is also used for specific indications.
Course Duration Ranges from a single day up to 5 days for most acute infections, or 7 to 10 days when oral therapy follows initial IV treatment.

Administration Conditions and Preparation

Oral Administration Context: Azitrix tablets and oral suspension may be taken irrespective of food. However, 250 mg capsules must be taken on an empty stomach, meaning at least one hour before or two hours after a meal. Pediatric dosing is based on body weight (mg/kg) rather than fixed adult amounts.

IV Administration: Intravenous Azitrix requires a two-step preparation: initial reconstitution followed by further dilution before use. The resulting solution must be administered as a slow infusion over a period of not less than 60 minutes. It is specified that the solution must not be given as a rapid IV bolus or intramuscular injection.

This structured use protocol ensures proper delivery and absorption of Azithromycin across its various available forms.

Recent Clinical Evidence

Research Evidence Overview for Azitrix

This section summarizes the official research—primarily randomized controlled trials (RCTs) and meta-analyses—that is relevant to the approved uses of Azitrix, focusing on the type of evidence available, the patient groups studied, and the reported scope of the research. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Respiratory and Ear Infections: Pneumonia and Otitis Media

The body of research exploring the use of Azitrix in respiratory and ear contexts exists, largely derived from Randomized Controlled Trials. For Community-Acquired Pneumonia (CAP), research primarily included adults and children (those ge 6 months of age). These trials monitored outcomes such as measurements of clinical success and pathogen clearance. Regulatory syntheses categorize the evidence as High quality. Research exploring Acute Otitis Media (AOM) in pediatric patients is also generally categorized as High quality, focusing on changes in symptom intensity and clinical failure rates. The research noted that factors related to the taste of the oral suspension formulation were observed to complicate adherence during trials.

Evidence for Genital Infections and Microbiological Clearance

The research base for certain Genital Chlamydial and Gonococcal Infections is derived from Randomized Controlled Trials. Research primarily focused on the key outcome of microbiological clearance—the documented clearance of the pathogen—which was systematically assessed 3–4 weeks post-treatment. The research examining Chlamydia trachomatis clearance is categorized as High quality. However, data show patterns related to rapid resistance emergence in Neisseria gonorrhoeae. Research indicates that due to this observed resistance, the pattern of studies has shifted toward evaluating combination therapy regimens.

Evidence Gaps and Areas of Uncertainty

The evidence highlights what is known—and what is still uncertain. Clinical trials primarily focus on the immediate and short-term response. As a result, there is limited information for long-term outcomes related to the sustained patterns of symptom evolution or the frequency of recurrence beyond the defined study periods. A significant area of uncertainty involves the impact of the documented, increasing rate of macrolide resistance globally, which may affect the observed outcomes compared to results from older trials. Comparative evidence is lacking versus some non-macrolide agents.

Key Studies & References

  1. Acute otitis media: clinical practice guideline (Systematic Review/Guideline)

Frequently Asked Questions (FAQ)

Common questions about Azitrix (FAQ)

Q: Does Azitrix require any special monitoring by a healthcare provider?

A: Regulatory documents state that monitoring of the International Normalized Ratio (INR) is generally expected when Azitrix is co-administered with oral anticoagulants like Warfarin. Caution and close observation are specified for patients with certain cardiovascular risks, such as pre-existing QT prolongation. Neonates receiving Azitrix are also specified for monitoring to check for a rare gastrointestinal condition called Infantile Hypertrophic Pyloric Stenosis (IHPS).

Q: Can children or teenagers use Azitrix?

A: Official prescribing information indicates that Azitrix is used to treat certain bacterial infections in children aged 6 months and older, with dosing calculated based on body weight. Safety and effectiveness have not been established in infants younger than 6 months. Certain dosage forms, like the tablet, are also not typically specified for children weighing less than 45 kg.

Q: What kind of infections is Azitrix most commonly used against?

A: Regulatory documents state that Azitrix is indicated for treating infections caused by susceptible bacteria. This includes common types of respiratory tract infections, such as Community-Acquired Pneumonia and Acute Bacterial Sinusitis, as well as certain skin and ear infections.

Q: What if I already take a lot of different medications—does that increase the risk of problems with Azitrix?

A: Official documents list specific drug classes that can interact with Azitrix, such as certain heart medications or anticoagulants. When an individual takes multiple medications, the potential for complex interactions increases. Due to this potential complexity, the official guidance highlights the necessary step of reviewing all current medications with a health professional before treatment begins.

Q: What is the purpose of the 'inactive ingredients' listed in Azitrix?

A: The active ingredient, Azithromycin, is combined with inactive ingredients, or excipients. These components are required for the manufacturing process, to ensure the stability of the medicine, and to facilitate its proper delivery in the body. Official patient information sheets may include warnings about specific excipients for individuals with known intolerances, such as lactose.

Q: What should be done if I experience a mild rash while taking Azitrix?

A: Regulatory labeling notes that treatment must be immediately stopped if signs of a severe allergic reaction or a severe, life-threatening skin reaction are observed. Since a rash is an adverse reaction, the official guidance indicates that any change in skin condition warrants communication with a healthcare provider for evaluation.

Q: What evidence supports the claim that Azitrix is generally well-tolerated?

A: Official regulatory documents list the frequency of common and serious adverse reactions reported during clinical use. The lower incidence rates of serious side effects compared to common gastrointestinal upset are factors typically considered when evaluating the general tolerability profile of a medicine. The official label specifies the frequency of both common and serious events.

Q: How quickly does Azitrix usually start working?

A: According to the official clinical pharmacology information, the highest concentrations of Azitrix in the bloodstream are typically reached two to three hours after an oral dose. This medicine has unique properties that allow it to be highly concentrated within body tissues, which contributes to its prolonged antibacterial action.

Q: What is the difference between Azitrix and other medicines used for similar conditions?

A: Regulatory documents classify Azitrix as an azalide, which is a specific class of macrolide antibiotics. Official information notes that it is a semi-synthetic derivative of an older macrolide and highlights its specific pharmacokinetic properties, such as being widely distributed into body tissues and having a prolonged duration of action.

Q: Is it true that Azitrix can interact with vitamins or supplements?

A: While regulatory documents specifically detail interactions with certain prescription drugs and antacids, general guidance from national health bodies advises patients to always disclose all substances being taken. This includes herbal remedies, vitamins, and supplements, as these may not have been specifically tested for interaction with Azitrix.

Q: What happens if I stop taking Azitrix too early?

A: The official product label emphasizes that Azitrix is expected to be taken for the full prescribed duration to reduce the development of drug-resistant bacteria. Discontinuing the full course prematurely can lead to the survival of the bacteria and the potential development of antibiotic resistance.

Q: Is Azitrix generally safe for older people?

A: Official documents specify that caution is generally required for elderly patients. This is because this population may be more susceptible to the development of certain heart rhythm issues (arrhythmias) associated with Azitrix, especially if they have pre-existing risk factors.

Q: How long does Azitrix stay in your body after the last dose?

A: Official clinical pharmacology information indicates that Azitrix has a prolonged terminal elimination half-life, averaging approximately 68 hours in adults. Because of the way the drug is absorbed and held in the tissues, it can continue to have antibacterial activity for several days after the medication course is finished.

Q: Do I need to avoid any specific types of food or drink while on Azitrix?

A: Official labeling dictates a specific restriction for certain antacids, which must be taken at least two hours before or two hours after Azitrix. Beyond this required separation from antacids, the drug labeling does not specify restrictions on other general types of food or drinks.

Q: Does Azitrix affect birth control pills?

A: Some regulatory reviews note that Azitrix may potentially reduce the effectiveness of oral contraceptives containing ethinyl estradiol in certain individuals. This is stated to potentially increase the risk of pregnancy or breakthrough bleeding.

Q: Is it safe to use Azitrix if I am lactose intolerant?

A: Certain formulations of Azitrix tablets contain lactose monohydrate as a non-active ingredient. For individuals with known hereditary problems related to sugar absorption or intolerance, the official guidance suggests communication with a healthcare professional regarding the use of formulations containing lactose.

Q: Is Azitrix a Schedule II controlled substance?

A: According to official classification records from governmental drug agencies, Azitrix (Azithromycin) is generally not designated as a controlled medication under the U.S. Controlled Substances Act.

Q: Does Azitrix have a risk of causing confusion or mental fogginess?

A: Regulatory documents list central nervous system effects such as dizziness and insomnia (trouble sleeping) as uncommon side effects. Though rare, post-marketing reports have also included instances of confusion and delirium.

Q: Is Azitrix considered a first-line treatment for its main indication?

A: Official prescribing information indicates that Azitrix is often used as a specific alternative therapy for certain infections (like pharyngitis/tonsillitis) in patients who cannot tolerate or use the recommended first-line agent, such as penicillin. Therefore, it is not universally classified as a first-line treatment.

Q: Does Azitrix affect the ability to drive or operate machinery?

A: Official regulatory warnings and patient information state that Azitrix may cause side effects such as dizziness or drowsiness (somnolence). Caution is generally advised, and individuals are expected to be aware of these potential effects.

Q: Can Azitrix change the results of laboratory tests?

A: While the regulatory label does not specifically detail interference with routine lab test results, official clinical trial protocols routinely include safety laboratory testing. This is done to monitor for potential drug-induced changes in key markers like liver enzymes and kidney function.

Q: Are there generic versions of Azitrix available?

A: Yes, regulatory records confirm that a lower-cost generic version of the active ingredient, Azithromycin, has been approved and is generally available for a number of the different dosage forms.

Q: Does Azitrix cause dry mouth?

A: Regulatory documents list dry mouth as an adverse reaction that has been reported in post-marketing use or less common findings. It is not, however, listed among the most frequently reported common side effects in the official labeling.

Q: Is Azitrix known to cause sleeplessness or insomnia?

A: Yes, insomnia, which means trouble falling or staying asleep, is specifically listed as an uncommon side effect in regulatory documents.

Q: How do doctors monitor the effectiveness of Azitrix treatment?

A: Official information derived from clinical trial outcomes indicates that effectiveness is monitored primarily by assessing the patient's clinical response. This involves the doctor evaluating the improvement of symptoms and, in certain types of infections, confirming the microbiological clearance of the targeted pathogen.

How should Azitrix be stored and disposed of?

How to Store and Dispose of Azitrix

Azitrix (azithromycin) tablets and unconstituted powder must be stored at Controlled Room Temperature, which ranges from 15 C to 30 C (59 F to 86 F), protected from excessive moisture. Keep all formulations in the original, tightly closed container and out of the sight and reach of children.


Storage and Stability of Oral Suspension

The reconstituted liquid suspension must not be refrigerated and should be stored at or below 30 C (86 F). The suspension is stable for a maximum of 10 days; any unused portion must be properly discarded after this period.


Disposal Requirements

Unused or expired medication must not be disposed of via wastewater (such as down the sink or toilet). The product should be discarded through an official drug take-back program or, if unavailable, mixed with an unappealing substance like used coffee grounds, sealed in a bag, and placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azitrix found in:

A-Z Index: